<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34218511</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2163-8306</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>CPT: pharmacometrics &amp; systems pharmacology</Title>
          <ISOAbbreviation>CPT Pharmacometrics Syst Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure.</ArticleTitle>
        <Pagination>
          <StartPage>1081</StartPage>
          <EndPage>1091</EndPage>
          <MedlinePgn>1081-1091</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/psp4.12676</ELocationID>
        <Abstract>
          <AbstractText>To characterize and compare various medicines for chronic heart failure (CHF), changes in circulatory physiological parameter during pharmacotherapy were investigated by a model-based meta-analysis (MBMA) of circulatory physiology. The clinical data from 61 studies mostly in patients with heart failure with reduced ejection fraction (HFrEF), reporting changes in heart rate, blood pressure, or ventricular volumes after treatment with carvedilol, metoprolol, bisoprolol, bucindolol, enalapril, aliskiren, or felodipine, were analyzed. Seven cardiac and vasculature function indices were estimated without invasive measurements using models based on appropriate assumptions, and their correlations with the mortality were assessed. Estimated myocardial oxygen consumption, a cardiac load index, correlated excellently with the mortality at 3, 6, and 12 months after treatment initiation, and it explained differences in mortality across the different medications. The analysis based on the present models were reasonably consistent with the hypothesis that the treatment of HFrEF with various medications is due to effectively reducing the cardiac load. Assessment of circulatory physiological parameters by using MBMA would be insightful for quantitative understanding of CHF treatment.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Takaoka</LastName>
            <ForeName>Ryota</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soejima</LastName>
            <ForeName>Yukako</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Regulartory Affairs, Sanofi K.K., Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guro</LastName>
            <ForeName>Sayuri</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoshioka</LastName>
            <ForeName>Hideki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Hiromi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suzuki</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hisaka</LastName>
            <ForeName>Akihiro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>CPT Pharmacometrics Syst Pharmacol</MedlineTA>
        <NlmUniqueID>101580011</NlmUniqueID>
        <ISSNLinking>2163-8306</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002317">Cardiovascular Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002317" MajorTopicYN="N">Cardiovascular Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Y.S. is an employee of Sanofi K.K. However, Sanofi K.K. is not involved in this analysis. S.G. was involved in this study before she joined Astellas Pharma Inc. All other authors declared no competing interests for this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>4</Day>
          <Hour>21</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34218511</ArticleId>
        <ArticleId IdType="pmc">PMC8452295</ArticleId>
        <ArticleId IdType="doi">10.1002/psp4.12676</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137‐e161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28455343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021‐3104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30165516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poole‐Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7‐13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12853193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MERIT‐HF Study Group
. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT‐HF). Lancet. 1999;353:2001‐2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10376614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CIBIS‐II Investigators and Committees
. The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. Lancet. 1999;353:9‐13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10023943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Investigators SOLVD, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293‐302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2057034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziff OJ, Samra M, Howard JP, et al. Beta‐blocker efficacy across different cardiovascular indications: an umbrella review and meta‐analytic assessment. BMC Med. 2020;18:103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7199339</ArticleId>
            <ArticleId IdType="pubmed">32366251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reil JC, Tardif J‐C, Ford I, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62:1977‐1985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23933545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta‐analysis: beta‐blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784‐794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19487713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zannad F, Garcia Angeles A, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082‐1094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23787718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shigemi K, Fuke S, Une D, et al. Physiological insights of recent clinical diagnostic and therapeutic technologies for cardiovascular diseases. J Physiol Sci. 2017;67:655‐672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5698391</ArticleId>
            <ArticleId IdType="pubmed">28681363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Böhm M, Deutsch HJ, Hartmann D, Rosée KL, Stäblein A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol. 1997;30:992‐996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9316529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ping P, Gelzer‐Bell R, Roth DA, Kiel D, Insel PA, Hammond HK. Reduced beta‐adrenergic receptor activation decreases G‐protein expression and beta‐adrenergic receptor kinase activity in porcine heart. J Clin Invest. 1995;95:1271‐1280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC441466</ArticleId>
            <ArticleId IdType="pubmed">7883975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrese V, Taglialatela M. New advances in beta‐blocker therapy in heart failure. Front Physiol. 2013;4:323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3827547</ArticleId>
            <ArticleId IdType="pubmed">24294204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubon C, Mistry NB, Grundvold I, Halvorsen S, Kjeldsen SE, Westheim AS. The role of beta‐blockers in the treatment of chronic heart failure. Trends Pharmacol Sci. 2011;32:206‐212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura K, Fushimi K, Kouchi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor‐alpha and angiotensin II. Circulation. 1998;98:794‐799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9727550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatterjee S, Biondi‐Zoccai G, Abbate A et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta‐analysis. BMJ. 2013;346: f55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3546627</ArticleId>
            <ArticleId IdType="pubmed">23325883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DerSimonian R, Laird N. Meta‐analysis in clinical trials. Control Clin Trials. 1986;7:177‐188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3802833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sunagawa K, Maughan WL, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol. 1983;245:H773‐H780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6638199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442‐451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22281246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86:513‐521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1638719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanoverschelde JL, Wijns W, Essamri B et al. Hemodynamic and mechanical determinants of myocardial O2 consumption in normal human heart: effects of dobutamine. Am J Physiol. 1993;265(6 Pt 2):H1884‐H1892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8285227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suga H. Total mechanical energy of a ventricle model and cardiac oxygen consumption. Am J Physiol. 1979;236:H498‐H505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">426086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takaoka H, Takeuchi M, Odake M, et al. Comparison of hemodynamic determinants for myocardial oxygen consumption under different contractile states in human ventricle. Circulation. 1993;87:59‐69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8419025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chemla D, Hébert JL, Coirault C et al. Total arterial compliance estimated by stroke volume‐to‐aortic pulse pressure ratio in humans. Am J Physiol. 1998;274:H500‐H505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9486253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metra M, Nodari S, Dei Cas L. Beta‐blockade in heart failure. Am J Cardiovasc Drugs. 2001;1(1):3–14
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14728047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aoki K, Sato K. Pathophysiological background for the use of calcium antagonists. J Cardiovasc Pharmacol. 1985;7:S28‐S32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2412008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harting J, Becker KH, Bergmann R et al. Pharmacodynamic profile of the selective beta 1‐adrenoceptor antagonist bisoprolol. Arzneimittelforschung. 1986;36:200‐208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2870720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beta‐Blocker Evaluation of Survival Trial Investigators
, Eichhorn EJ, Domanski MJ, Krause‐Steinrauf H, Bristow MR, Lavori PW. A trial of the beta‐blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659‐1667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11386264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309:1125‐1135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23478743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V‐HeFT III. Vasodilator‐Heart Failure Trial (V‐HeFT) Study Group. Circulation. 1997;96:856‐863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9264493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaye DM, Johnston L, Vaddadi G, Brunner‐LaRocca H, Jennings GL, Esler MD. Mechanisms of carvedilol action in human congestive heart failure. Hypertension. 2001;37:1216‐1221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11358931</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
